Tier 3 — preclinical

Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy

Diguet N, Trammell SAJ, Tannous C, Deloux R, Piquereau J, Mougenot N, Gouge A, Gressette M, Manoury B, Blanc J, Breton M, Decaux JF, Lavery GG, Baczkó I, Zoll J, Garnier A, Li Z, Brenner C, Mericskay M
Circulation 2018 137; 21; 2256-2273

Bibliography

PubMed
PMID 29217642
PubMed Central
PMC6954688
DOI
10.1161/circulationaha.116.026099
Funding
Indexed grant support includes NIGMS NIH HHS, Wellcome Trust. The complete funding declaration is not specified in the accessible abstract.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignPreclinical animal study with supporting assays as applicable
ModelMice, cardiomyocytes and human heart biopsies
SampleCardiomyopathy and pressure-overload mice; separate human heart tissue
InterventionDietary NR and cellular NAD+ pathway experiments
DurationModel-specific cardiac follow-up
EndpointsModel-specific physiological outcomes; Biochemical or functional measures reported in the study

What the study showed, in plain terms

NR supported cardiac NAD+ metabolism and attenuated heart-failure development in selected mouse models.

Key findings

NR supported cardiac NAD+ metabolism and attenuated heart-failure development in selected mouse models.

What this study can and cannot tell us

The human component was tissue observation, not an NR treatment trial. Preclinical cardiac effects do not establish fewer human admissions or deaths.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology